Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179337 | 0.74 | NCF1 (0.40) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL23682984 | 0.72 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL19732129 | 0.72 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL13396211 | 0.72 | CYP2D6 (0.42) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL17791236 | 0.72 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL13750467 | 0.72 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL2706991 | 0.72 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL22797 | 0.71 | — | — | |
| SCHEMBL5270433 | 0.71 | — | — | |
| SCHEMBL5615220 | 0.71 | EPHX1 (0.42) | CYP2D6KCNH2HRH3EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | CYP2D6 4032/4885KCNH2 3926/4885HRH3 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.